Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.
Breast Cancer Res Treat
; 119(1): 127-36, 2010 Jan.
Article
em En
| MEDLINE
| ID: mdl-19690954
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Receptor ErbB-2
/
Taxoides
/
Anticorpos Monoclonais
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article